Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H2O4.Fe |
Molecular Weight | 169.901 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Fe++].[O-]C(=O)\C=C\C([O-])=O
InChI
InChIKey=PMVSDNDAUGGCCE-TYYBGVCCSA-L
InChI=1S/C4H4O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H,(H,5,6)(H,7,8);/q;+2/p-2/b2-1+;
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H2O4 |
Molecular Weight | 114.0563 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: http://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttp://www.druglead.com/cds/ferrous-iodide.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.drugs.com/inactive/ferrous-oxide-389.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/672678 | https://www.ncbi.nlm.nih.gov/pubmed/27138526 | https://www.ncbi.nlm.nih.gov/pubmed/20685224 | https://www.ncbi.nlm.nih.gov/pubmed/26911730
Sources: http://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfhttp://www.druglead.com/cds/ferrous-iodide.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/14116934DOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016http://www.foodchemadditives.com/products/Ferrous-Lactatehttps://www.ncbi.nlm.nih.gov/pubmed/16694502http://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.drugs.com/inactive/ferrous-oxide-389.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/672678 | https://www.ncbi.nlm.nih.gov/pubmed/27138526 | https://www.ncbi.nlm.nih.gov/pubmed/20685224 | https://www.ncbi.nlm.nih.gov/pubmed/26911730
Iron(II) oxide or ferrous oxide is the inorganic compound with the formula FeO. One of several iron oxides, it is a black-colored powder that is sometimes confused with rust, which consists of hydrated iron(III) oxide (ferric oxide). Iron(II) oxide also refers to a family of related non-stoichiometric compounds, which are typically iron deficient with compositions ranging from Fe0.84O to Fe0.95O. Iron(II) oxide makes up approximately 9% of the Earth's mantle. Within the mantle, it may be electrically conductive, which is a possible explanation for perturbations in Earth's rotation not accounted for by accepted models of the mantle's properties. Iron(II) oxide is used as a pigment. It is FDA-approved for use in cosmetics and it is used in some tattoo inks. It can also be used as a phosphate remover from home aquaria.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
Curative | RADIOGARDASE Approved UseInsoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date1.06496642E12 |
|||
PubMed
Title | Date | PubMed |
---|---|---|
FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS. | 1932 Jul 1 |
|
FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS. | 1932 Nov 11 |
|
THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A. | 1932 Sep 30 |
|
[Ferrous lactate as an oral iron preparation for therapeutic use]. | 1954 Nov 27 |
|
Clinical appraisal of drugs with special reference to a new chelate hematinic. | 1957 Jul 11 |
|
[Historical notes on the therapy of depression]. | 1986 Nov 22 |
|
Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis. | 2007 |
|
Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. | 2009 |
|
Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study. | 2009 Nov 15 |
|
Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
Tolerability of different oral iron supplements: a systematic review. | 2013 Apr |
|
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows. | 2013 Jul |
|
A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts. | 2014 |
|
Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes. | 2015 Jun 22 |
|
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes. | 2017 Mar 13 |
|
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:53:44 UTC 2023
by
admin
on
Wed Jul 05 22:53:44 UTC 2023
|
Record UNII |
R5L488RY0Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B03AD02
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
||
|
WHO-ATC |
B03AA02
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
||
|
CFR |
21 CFR 184.1307D
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
||
|
WHO-VATC |
QB03AA02
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
||
|
WHO-VATC |
QB03AD02
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
||
|
CFR |
21 CFR 172.350
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1200640
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
205-447-7
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
DB14491
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
141-01-5
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
24941
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
R5L488RY0Q
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
C61763
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
C031621
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
CONCEPT | Dietary Supplement | ||
|
FERROUS FUMARATE
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | Description: A fine, reddish orange or reddish brown powder.Solubility: Slightly soluble in water; very slightly soluble in ethanol (~750 g/l) TS.Category: Iron supplement.Storage: Ferrous fumarate should be kept in a well-closed container.Definition: Ferrous fumarate contains not less than 93.0% and not more than 101.0% of C4H2FeO4, calculated with reference to the dried substance. | ||
|
486120
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
ALTERNATIVE | |||
|
M5343
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB13865MIG
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
R5L488RY0Q
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
DTXSID7047148
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
6433164
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
IRON(II) FUMARATE
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
100000090445
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY | |||
|
4261
Created by
admin on Wed Jul 05 22:53:44 UTC 2023 , Edited by admin on Wed Jul 05 22:53:44 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |